Hugh D. Falls

Medicine · Health Sciences

13h-index798citations28works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(13), Regulation of Appetite and Obesity(10), Monoclonal and Polyclonal Antibodies Research(9), Lung Cancer Treatments and Mutations(7), Biochemical Analysis and Sensing Techniques(5)

Publications28 total

Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
2023Open Access
Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
2023Open Access
Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
2023Open Access
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023Open Access
Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023Open Access
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023Open Access
Data from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
2023Open Access
Supplementary Table 1, Table 2; Supplementary Figure 1 from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
2023Open Access
Data from ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
2023Open Access
Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
2023Open Access
Figure S1 from Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
2023Open Access
Supplementary Data from Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
2023Open Access
Synergistic therapeutic benefit by combining the antibody drug conjugate, depatux-m with temozolomide in pre-clinical models of glioblastoma with overexpression of EGFR
Journal of Neuro-Oncology·2021· 10 cited
Targeting Multiple EGFR-expressing Tumors with a Highly Potent Tumor-selective Antibody–Drug Conjugate
Molecular Cancer Therapeutics·2020· 42 cited
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Molecular Cancer Therapeutics·2018· 48 citedOpen Access
ABT-414, an Antibody–Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
Molecular Cancer Therapeutics·2016· 175 citedOpen Access
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody
Molecular Cancer Therapeutics·2015· 79 cited
Identification and Preliminary Characterization of a Potent, Safe, and Orally Efficacious Inhibitor of Acyl-CoA:Diacylglycerol Acyltransferase 1
Journal of Medicinal Chemistry·2012· 34 citedOpen Access
Identification of diamino chromone-2-carboxamides as MCHr1 antagonists with minimal hERG channel activity
Bioorganic & Medicinal Chemistry Letters·2006· 15 citedOpen Access
Characterization of ghrelin receptor activity in a rat pituitary cell line RC-4B/C
Journal of Molecular Endocrinology·2006· 29 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Edward B. Reilly(17), Erwin R. Boghaert(16), Kedar S. Vaidya(16), Michael J. Mitten(16), Peter J. DeVries(11), Jonathan A. Meulbroek(11), Fritz G. Buchanan(11), Andrew M. Scott(11), Christine A. Collins(10), Diana Cao(10), Hui Gan(10), Wiweka Kaszubska(8), Verlyn G. Schaefer(8), Hing L. Sham(8), Andrew C. Phillips(8), Joann P. Palma(7), Zhili Xin(7), Neal Goodwin(6), Hongyu Zhao(6), Martin J. Voorbach(6)